Skip to Main Content

299

Views

0

CrossRef citations to date

0

Altmetric

Original Research

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study

David Gordon1 Research and Development, Aclaris Therapeutics, Inc., Wayne, PA, USACorrespondence[email protected]
View further author information

,

Edward T Hellriegel1 Research and Development, Aclaris Therapeutics, Inc., Wayne, PA, USAView further author information

,

Heidi Rath Hope2 Research and Development, Aclaris Therapeutics, Inc., and Confluence Discovery Technologies, Inc., St. Louis, MO, USAView further author information

,

David Burt1 Research and Development, Aclaris Therapeutics, Inc., Wayne, PA, USAView further author information

&

Joseph B Monahan2 Research and Development, Aclaris Therapeutics, Inc., and Confluence Discovery Technologies, Inc., St. Louis, MO, USAView further author information